Злокачественное новообразование бронхов и легкого. Клинические рекомендации 2022

1. Давыдов М.И., Полоцкий Б.Е. Рак легкого. М.: Радикс, 1994. [Davydov MI, Polotskii BE. Lung cancer. Moscow: Radiks, 1994 (in Russian)].
2. Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: ГЭОТАР-Медиа, 2000 [Trakhtenberg AKh, Chissov VI. Clinical oncopulmonology. Moscow: GEOTAR-Media, 2000 (in Russian)].
3. The health consequences of smoking: a report of the Surgeon General. Available at: https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/consequences-smoking-factsheet/i.... Accessed: 26.08.2022.
4. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020 [The state of cancer care for the population of Russia in 2019. Ed. by AD Kaprin, VV Starinskii, AO Shakhzadova. Moscow: MNIOI im. PA Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2020 (in Russian)].
5. Stahel R, Peters S, Garassino M. Thoracic tumours essentials for clinicians. ESMO Press, 2014.
6. WHO classification of tumours of the lung, pleura, thymus and heart, 2015.
7. The AJCC Cancer staging manual. 8th ed. Springer, 2017.
8. Grunnet M, Sorensen JB. Carcinoembrionic antigen (CEA) as a tumor marker in lung cancer. Lung Cancer. 2012;76:138-43.
9. Planchard D, Popat S, Kerr R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192-237.
10. NCCN Guidelines. Non-small cell lung cancer. Version 7.2019. Available at: https://www.nccn.org/guidelines/category_1. Accessed: 26.08.2022.
11. Travis DW, Brambilla E, Burke AP, et al. Classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2015.
12. Lung cancer. Ed. by FV Fossella, JB Putnam, R Komaki. NewYork: Springer, 2003.
13. Schrump DS, Carter D, Kelsey CR, et al. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg cancer. Principles and practice of oncology. Ed. by VT DeVita Jr, TS Lawrence, SA Rosenberg, et al. Philadelphia: Lippincott Williams and Wilkins, 2011.
14. Трахтенберг А.Х., Чиссов В.И., Франк Г.А. Нейроэндокринные опухоли легких. М.: Практическая медицина, 2012 [Trakhtenberg AKh, Chissov VI, Frank GA. Neuroendocrine lung tumors. Moscow: Prakticheskaia meditsina, 2012 (in Russian)].
15. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией – стандарт в хирургическом лечении больных немелкоклеточным раком легкого Т1–2N0М0. Вопросы онкологии. 2015;61(3):413-7 [Allakhverdiev AK, Davydov MM. Torakoskopicheskaia lobektomiia s mediastinal'noi limfodissektsiei standart v khirurgicheskom lechenii bol'nykh nemelkokletochnym rakom legkogo T1–2N0M0. Voprosy onkologii. 2015;61(3):413-7 (in Russian)].
16. Higuchi M, Yaginuma H, Yonechi A, et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer. J Cardiothorac Surg. 2014;9:88-92.
17. Lindberg K, Nyman J, Riesenfeld Källskog V, et al. Long-term of a results of prospective trial phase II of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. Acta Oncol. 2015;54:1096-104.
18. Zhang T, Guo Q, Zhang Y, et al. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. J Can Res Ther. 2018;14:139-44.
19. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-97.
20. Arriagada R, Dunant A, Pignon JP. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35-42. DOI:10.1200/JCO.2009.23.2272
21. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267-77.
22. Aureperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol. 2010;28:2181-90.
23. Tsitsias T, Boulemden A, Ang K, et al. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. J Eur Cardiothorac Surg. 2014;45:882-7.
24. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172-8.
25. Usami N, Yokoi K, Hasegawa Y, et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol. 2010;15:583-7.
26. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516-24.
27. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369(9577):1929-37. DOI:10.1016/S0140-6736(07)60714-4
28. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043-51.
29. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-24.
30. Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10(10):CD002142. DOI:10.1002/14651858.CD002142.pub4
31. Arriagada R, Bergman B, Dunant A, et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-60.
32. Kreuter M, Vansteenkiste J, Fishcer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013;24:986-92.
33. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-60.
34. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.
35. Gridelli С, Chen T, Ko A, et al. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug Des Devel Ther. 2018;12:1445-51. DOI:10.2147/DDDT.S155750
36. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer. 2015;87:232-40.
37. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953-62.
38. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol. 2002;20:3454-60.
39. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-99.
40. Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-7. DOI:10.1016/j.jtho.2020.12.015
41. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(30):3488-515.
42. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25:1681-90.
43. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
44. Yang JC, Wu YI, Shuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR-mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX‑Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol. 2015;16:141-51.
45. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25.
46. Solomon BJ, Mok T, Kim DW, et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2013;371:2167-77.
47. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND 4): a randomized, open-label, phase 3 study. Lancet. 2017;389:917-29.
48. Camidge DR, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX global study of alectinib (ALC) versus crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol. 2018;36(Suppl.):9043.
49. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-16.
50. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017;28(8):2002-8.
51. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8:1556-62.
52. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer. 1998;34:1710-4.
53. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317-23.
54. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-50.
55. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol. 2008;26:3543-51.
56. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909-24. DOI:10.1016/j.jtho.2021.07.009
57. Barlesi F, Scherpereel A, Rittmeywr A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. J Clin Oncol. 2013;31:3004-11.
58. Takagi Y, Hosomi Y, Sunami K, et al. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin-Pemetrexed Therapy for Non-Small Cell Lung Cancer. Oncologist. 2014;19(11):1194-9. DOI:10.1634/theoncologist.2014-0221
59. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
60. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010;5:CD007309.
61. Azzolic G, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology clinical practice guideline update of chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825-31.
62. D’Addario G, Pintile M, Leighi NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature. J Clin Oncol. 2005;23:2926-36.
63. Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31:2849-53.
64. Переводчикова Н.И., Горбунова В.А. Руководство по химиотерапии опухолевых заболеваний. М.: Практическая медицина, 2015 [Perevodchikova NI, Gorbunova VA. Guidelines for chemotherapy of tumor diseases. Moscow: Prakticheskaia meditsina, 2015 (in Russian)].
65. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy in elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72.
66. Corre R, Greillier L, Le Caer H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34:1476-83.
67. Henry HD, Costa I, Goldwasser F, et al. Randomised, double-blind study of denosumab versus zoledronic acid in the treatment skeletal metastases in patients with advanced cancer (excluded breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32.
68. Zatloukal P, Kanitz E, Magyar P, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer. 1998;22:243-50.
69. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin- gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516-24. DOI:10.1200/JCO.2011.39.9782
70. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-62.
71. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol. 2009;27:591-8.
72. Hanna NH, Sheperd FA, Fossella FV, et al. Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
73. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-21.
74. Cardenal F, López-Cabrerizon MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(1):12-8.
75. Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112-24.
76. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33. DOI:10.1056/NEJMoa1606774
77. Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36(Suppl. 18):LBA4.
78. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-92. DOI:10.1056/NEJMoa1801005
79. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-51.
80. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab in first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301.
81. Gandhi I, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-92.
82. Sheperd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum – based chemotherapy. J Clin Oncol. 2000;18:2095-103.
83. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
84. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
85. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-65.
86. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-50.
87. Herbst R, Garon E, Kim DW, et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thoracic Oncol. 2017;12:254-5.
88. Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29(11):2208-13.
89. Garon E, Reck M, Rodríguez-Abreu D, et al. P3.02c-030 Use of a 200‑Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: IT. J Thorac Oncol. 2017;12(1):S1290-91. DOI:10.1016/j.jthе.2016.11.1825
90. Morrissey KM, Marchand M, Patel H, et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019;84(6):1257-67. DOI:10.1007/s00280-019-03954-8
91. Garassino M, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981-8.
92. Novello S, Kaiser R, Mellengaard A, et al. Analysis of patient-reported outcomes from the LUME-Lung I trial: a randomized, double-blind, placebo-controlled. Phase III study of second line nintedanib in patients non-small-cell lung cancer. Eur J Cancer. 2015;51:317-26.
93. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. The European Lung Cancer Working Party. Lung Cancer. 2000;29:67-73.
94. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300-8.
95. Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119:2754-64.
96. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897-907.
97. Planchard D, Popat S, Kerr R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192-237.
98. Ahn MJ, Kim SW, Cho BC, et al. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. Oncologist. 2014;19(7):702-3.
99. Cho BC, Kim DW, Bearz A, et al. ASCEND-8 – a randomized phase I study ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK) rearranged metastatic non-small-cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357-67. DOI:10.1016/j.jtho.2017.07.005
100. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394-400.
101. Riely GJ, Yu HA. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res. 2015;21(10):2221-6. DOI:10.1158/1078-0432.CCR-14-3154
102. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
103. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
104. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. DOI:10.1056/NEJMoa0810699
105. Sequst LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-34.
106. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-25. DOI:10.1056/NEJMoa1713137
107. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
108. Oxnard GR, Thress KS, Alden RS. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3375-82. DOI:10.1200/JCO.2016.66.7162
109. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71.
110. Shaw AT, Yeap BY, Solomon BJ, et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. J Clin Oncol. 2011;29(Suppl. 15):7507.
111. Moro-Sibilot D, Faivre L, Zalcman G, et al. Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSE phase II trial. J Clin Oncol. 2015;33:abstr8065.
112. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-9.
113. Pan J. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. Clin Drug Investig. 2019;39:1003-7.
114. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-6.
115. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984-93.
116. Planchard D, Smit EF, Groen HJM, et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D+ trametinib (T) in the phase II BRF113928 study. J Clin Oncol. 2017;35(Suppl.):аbstr9075.
117. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28:29-34.
118. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacisumab with paclitaxel/carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2010;5:1416-23.
119. Yang B, Lee H, Um SW, et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer. 2019;129:28-34.
120. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.
121. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711-7.
122. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data of meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91:710-7.
123. Priestman TJ, Dunn J, Brada M, et al. Final results of the Royal College of Radiologists’ Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol. 1996;8:308-15.
124. Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg Clin North Am. 1996;7:435-46.
125. Naruke T. Lymph node metastasis of lung cancer and associated surgery. Asian Med J. 1990;33(12):668-77.
126. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database. J Thorac Cardiovasc Surg. 2010;139:366-78.
127. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial. J Thorac Cardiovasc Surg. 2010;139:976-81.
128. Ginsberg RJ, Rubinstein LV. Randomised trial of lobectomy versus limited resection for Т1N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615‑22.
129. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350-7.
130. Мелкоклеточный рак легкого. Под ред. М.Б. Бычкова. М.: Фармарус принт Медиа, 2013 [Small cell lung cancer. Ed. by MB Bychkov. Moscow: Farmarus print Media, 2013 (in Russian)].
131. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543-52.
132. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-71.
133. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810-6.
134. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-8.
135. Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9.
136. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.
137. Kelly K. Irinotecan in small-cell lung cancer: current data. Clin Lung Cancer. 2001;2(Suppl. 2):S4-8. DOI:10.3816/clc.2001.s.001
138. Chang AY, Rubins J, Asbury R, et al. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol. 2001;28(4 Suppl. 14):10-3.  DOI:10.1053/sonc.2001.27607
139. Smit E, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77(2):347-51.
140. Slotman B, Faivre-Finn C, Kramer G, et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664-72.
141. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42.
142. Sommer MS, Trier K, Vibe-Petersen J, et al. Perioperative rehabilitation in operation for lung cancer (PROLUCA) – rationale and design. BMC Cancer. 2014;14:404. DOI:10.1186/1471-2407-14-404
143. Sebio R, Yáñez-Brage MI, Giménez-Moolhuyzen E, et al. Impact of a pre-operative pulmonary rehabilitation program on functional performance in patients undergoing video-assisted thoracic surgery for lung cancer. Arch Bronconeumol. 2016;52(5):231-2.
144. Sebio GR, Yáñez Brage MI, Giménez Moolhuyzen E, et al. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(3):486-97.
145. Barassi G, Bellomo RG, Di Iulio A, et al. Preoperative rehabilitation in lung cancer patients: yoga approach. Adv Exp Med Biol. 2018;1096:19-29.
146. Rogers LJ, Bleetman D, Messenger DE, et al. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. J Thorac Cardiovasc Surg. 2018;155(4):1843-52.
147. Li S, Zhou K, Che G, et al. Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res. 2017;9:657-70. DOI:10.2147/CMAR.S150500
148. Deng GE, Rausch SM, Jones LW, et al. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(Suppl. 5):e420S-36S.
149. Imperatori A, Grande A, Castiglioni M, et al. Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Interact Cardiovasc Thorac Surg. 2016;23:223-30.
150. Park H, Park J, Woo SY, et al. Effect of high-frequency chest wall oscillation on pulmonary function after pulmonary lobectomy for non-small cell lung cancer. Crit Care Med. 2012;40(9):2583-9.
151. Dhillon HM, van der Ploeg HP, Bell ML, et al. The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer. 2012;12:572.
152. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42:1409-26.
153. Janssen SM, Abbink JJ, Lindeboom R, Vliet Vlieland TP. Outcomes of pulmonary rehabilitation after treatment for non-small cell lung cancer stages I to IIIa: an observational study. J Cardiopulm Rehabil Prev. 2017;37(1):65-71.
154. Sun V, Raz DJ, Ruel N, et al. A multimedia self-management intervention to prepare cancer patients and family caregivers for lung surgery and postoperative recovery. Clin Lung Cancer. 2017;18(3):e151-9.
155. Batty GD, Russ TC, Stamatakis E, Kivimäki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ. 2017;356:j108.
156. Luszczynska A, Pawłowska I, Cieslak R, et al. Social support and quality of life among lung cancer patients: a systematic review. Psychooncology. 2013;22(10):2160-8.
157. Li M, Kennedy E, Byrne N, et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology. 2017;26:573-87.
158. Rivas-Perez H, Nana-Sinkam P. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med. 2015;109(4):437-42.
159. Andrea L, Kollasch J, Vandenberg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013;45:811-21.
160. Hilliard RE. Music therapy in hospice and palliative care: a review of the empirical data. Evid Based Complement Alternat Med. 2005;2(2):173-8.
161. Chen HY, Li SG, Cho WCS, Zhang ZJ. The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis. BMC Complement Altern Med. 2013;13:362.
162. Streckmann F, Zopf EM, Lehmann HC, et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014;44:1289-304.
163. Muzi JL, Look RM, Turner C, et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2012;30(Suppl. 15):9019.
164. Rick O, von Hehn U, Mikus E, et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics. 2016;38(2):85-94.
165. Kilinç M, Livanelioglu A, Yildirim SA, Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014;46(5):454-60.
166. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107418.
167. Ross M, Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs. 2017;21(2):226-33.
168. Hetkamp M, Bender J, Rheindorf N, et al. A Systematic Review of the Effect of Neurofeedback in Cancer Patients. Integr Cancer Ther. 2019;18:1534735419832361. DOI:10.1177/1534735419832361
169. Bade BC, Thomas DD, Scott JB, Silvestri GA. Increasing physical activity and exercise in lung cancer: reviewing safety, benefits, and application. J Thorac Oncol. 2015;10(6):861-71.
170. Bensadoun RJ, Nair RG. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg. 2015;33(10):487-91.
171. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372-90.
172. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. Ed. by C MacLeod. New York: Columbia University Press, 1949.
173. Hendriks LEL, Hermans BCM, Marieke van den Beuken-van Everdingen HJ, et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review. J Thorac Oncol. 2016;11(2):155-73.
174. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-35.
175. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018;13(9):1248-68.
176. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631-41.
177. Oxnard GR, Thress KS, Alden RS. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3375-82.  DOI:10.1200/JCO.2016.66.7162
178. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016;2(8):1014-22.
179. Kate S, Chougule A, Joshi A, et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl). 2019;10:1-10.
180. Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488-95.
181. Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302-16.
182. Passaro A, Pochesci A, Spitaleri G, et al. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7. J Thorac Dis. 2016;8(3):E217-20.
183. Takeda Y, Naka G, Yamaguchi Y, et al. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. BMC Cancer. 2020;20(1):951. DOI:10.1186/s12885-020-07424-w
184. NCCN Guidelines. Non-small cell lung cancer. Version 6.2020. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed: 26.08.2022.
185. Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44-56.
186. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-43.
187. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147.
188. Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019;3. DOI:10.1200/PO.19.00171
189. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):909-20.
190. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
191. Kowanetz M, Zou W, Shames DS, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Ann Oncol. 2016;27(Suppl. 6). DOI:10.1093/annonc/mdw363.25
192. Ramalingam S, Hellmann MD, Awad MM, et al. Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab + ipilimumab in first-line non-small cell lung cancer: identification of TMB cutoff from Checkmate 568. In: AACR Annual Meeting. 2018:abstr11317.
193. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.
194. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. In: 2018 Genitourinary Cancer Symposium. Lancet. 2018;391(10122):748-57. DOI:10.1016/S0140-6736(17)33297-X
195. Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71:177.
196. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv1-21.
197. Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162-74.
198. De Wever W. Role of integrated PET/CT in the staging of non-small cell lung cancer. JBR-BTR. 2009;92:124.
199. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl. 5):e211S-50S. DOI:10.1378/chest.12-2355
200. National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243-53. DOI:10.1148/radiol.10091808
201. National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980.
202. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-13.
203. Sadate A, Occean BV, Beregi JP, et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer. 2020;134:107.
204. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation-positive NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(Suppl. 18):LBA5. DOI:10.1200/JCO.2020.38.18_suppl.LBA5
205. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-704.
206. Ahn JS, Ahn YC, Kim JH, et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-6.  DOI:10.1200/JCO.2014.60.0130
207. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942-6.
208. Camidge RD, Ou SHI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol. 2014;32(Suppl. 5):abstr8001.
209. Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018;36(24):2532-7.
210. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-104.
211. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415-426.
212. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5.
213. Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28(2):292-7.
214. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47-51.
215. Spigel D, De Marinis F, Giaccone G, et al. IMpower110: Interim OS Analysis of a Phase III Study of Atezolizumab (atezo) vs Platinum-Based Chemotherapy (chemo) as 1L Treatment (tx) in PD-L1-selected NSCLC. ESMO 2019 (abstr:LBA78). Ann Oncol. 2019;30(Suppl. 5):v851-934.  DOI:10.1093/annonc/mdz394
216. Herbst RS, de Marinis F, Giaccone G, et al. LBA1 Clinical efficacy of Atezolizumab (Atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunochistochemistry (IHC) assys and by blood tumor mutational burden (bTMB): results from the IMpower110 study. Ann Oncol. 2019;30(Suppl. 11):xi62-8.
217. Chou CH, Hsu LF. Model-based simulation to support the extended dosing regimens of atezolizumab. Eur J Clin Pharmacol. 2021;77(1):87-93.  DOI:10.1007/s00228-020-02980-3
218. Hellman MD, Paz-Ares L, Caro RB, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020-31.
219. Reck M, Ciuleanu TD, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38(15):9501.
220. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68-75. DOI:10.1016/j.ejca.2020.02.016
221. Grohé C, Gleiber W, Haas S, et al. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncol. 2019;15(23):2699‑706. DOI:10.2217/fon-2019-0262
222. Nakagawa K, Garon E, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-69.
223. Garon E, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73.
224. Stinchcombe TE, Jänne PA, Wang X, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1448-55. DOI:10.1001/jamaoncol.2019.1847
225. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-64. DOI:10.1016/j.annonc.2020.04.478
226. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. J Clin Oncol. 2020;38(Suppl. 15):9002. DOI:10.1200/JCO.2020.38.15_suppl.9002
227. Chen Y, Paz-Ares L, Dvorkin M, et al. First-line durvalumab plus platinum-etoposide in ES-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. J Clin Oncol. 2020;38(Suppl. 15):9068.  DOI:10.1200/JCO.2020.38.15_suppl.9068.
228. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 3.2020. 2020. Available at: www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed: 06.09.2022.
229. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-67. DOI:10.1016/S1470-2045(18)30649-1
230. Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32(5):620-30. DOI:10.1016/j.annonc.2021.02.012
231. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected Stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15 Suppl.):8500. DOI:10.1200/JCO.2021.39.15_SUPPL.8500
232. Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clin Med Insights Oncol. 2020;14:1179554920951358. DOI:10.1177/1179554920951358
233. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer:  Version 3.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed: 06.09.2022.
234. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38(31):3592-603. DOI:10.1200/JCO.20.00505
235. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017;35(22):2490-8. DOI:10.1200/JCO.2016.71.5904
236. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491‑505. DOI:10.1016/j.annonc.2020.07.014
237. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann Oncol. 2018;29(9):1895‑902. DOI:10.1093/annonc/mdy263
238. Freiwald M, Schmid U, Fleury A, et al. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol. 2014;73(4):759-70. DOI:10.1007/s00280-014-2403-2
239. Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016;27(11):2103-10. DOI:10.1093/annonc/mdw322
240. Morrissey KM, Marchand M, Patel H, et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019;84(6):1257-67. DOI:10.1007/s00280-019-03954-8
241. Baverel PG, Dubois VFS, Jin CY, et al. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. Clin Pharmacol Ther. 2018;103(4):631-42. DOI:10.1002/cpt.982
242. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-95. DOI:10.1016/j.suponc.2011.05.002
243. Chen C, Li R, Yang T, et al. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Clin Ther. 2020;42(8):1494-507.e1. DOI:10.1016/j.clinthera.2020.05.019
244. Krishan S, Panditaratne N, Verma R, Robertson R. Incremental value of CT venography combined with pulmonary CT angiography for the detection of thromboembolic disease: systematic review and meta-analysis. AJR Am J Roentgenol. 2011;196(5):1065-72. DOI:10.2214/AJR.10.4745
245. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-56. DOI:10.1182/bloodadvances.2018024828
246. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74. DOI:10.1182/bloodadvances.2020003442
247. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. Version 1. 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed: 06.09.2022.
248. Kosaka Y, Rai Y, Masuda N, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer. 2015;23(4):1137-43. DOI:10.1007/s00520-014-2597-1
249. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176-89. DOI:10.1093/jac/dki448
250. Vincenzi B, Russo A, Terenzio A, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018;130:70-77. DOI:10.1016/j.critrevonc.2018.06.019
251. Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol. 2021;27(32):5376-91. DOI:10.3748/wjg.v27.i32.5376
252. Mao Z, Shen K, Zhu L, et al. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Oncol Res Treat. 2019;42(7-8):405-413. DOI:10.1159/000500204
253. Albakri A. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res. 2018;1(4). DOI:10.15761/TR.1000124
254. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73-84. DOI:10.1016/j.jchf.2021.09.004
255. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900-9. DOI:10.1016/j.ejca.2013.04.030
256. Li J, Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol. 2018;82(4):571-83. DOI:10.1007/s00280-018-3644-2
257. Martin EJ, Bruggeman AR, Nalawade VV, et al. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. J Natl Compr Canc Netw. 2020;18(5):569-74. DOI:10.6004/jnccn.2019.7524
258. de van der Schueren MAE, Laviano A, Blanchard H, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018;29(5):1141-53. DOI:10.1093/annonc/mdy114
259. Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open. 2018;3(2):e000301. DOI:10.1136/esmoopen-2017-000301
260. NCCN guidelines. Management of Immunotherapy-Related Toxicities.  Version 4. 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed: 06.09.2022. 
261. Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6(1):103. DOI:10.1186/s40425-018-0412-0
262. Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv126-42. DOI:10.1093/annonc/mdy145
263. Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl. 5):v261-5. DOI:10.1093/annonc/mdq197
264. Ohashi Y, Uemura Y, Fujisaka Y, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci. 2013;104(4):481-5. DOI:10.1111/cas.12105
265. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52(1):18-29.  DOI:10.3109/0284186X.2012.702921
266. Fallon M, Giusti R, Aielli F, et al; ESMO Guidelines Committee. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166-91. DOI:10.1093/annonc/mdy152
267. Capozzi VA, Monfardini L, Sozzi G, et al. Peripherally Inserted Central Venous Catheters (PICC) versus totally implantable venous access device (PORT) for chemotherapy administration: a meta-analysis on gynecological cancer patients. Acta Biomed. 2021;92(5):e2021257. DOI:10.23750/abm.v92i5.11844
268. Fallon M, Giusti R, Aielli F, et al. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines Ann Oncol. 2018;29(Suppl. 4):iv166-91. DOI:10.1093/annonc/mdy152
269. Giuliani M, Mathew AS, Bahig H, et al. SUNSET: Stereotactic Radiation for Ultracentral Non- Small-Cell Lung Cancer-A Safety and Efficacy Trial. Clin Lung Cancer. 2018;19(4):e529-32. DOI:10.1016/j.cllc.2018.04.001
270. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833-9. DOI:10.1200/JCO.2006.07.5937
271. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68-75. DOI:10.1016/j.ejca.2020.02.016
272. Comis RL, Friedland DM, Good BC. The role of oral etoposide in non-small cell lung cancer. Drugs. 1999;58(Suppl. 3):21-30. DOI:10.2165/00003495-199958003-00004
273. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810-6.  DOI:10.1093/annonc/mdq036
274. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for Еuropean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. DOI:10.1016/S1470-2045(11)70393-X

________________________________________________

1. Davydov MI, Polotskii BE. Lung cancer. Moscow: Radiks, 1994 (in Russian).
2. Trakhtenberg AKh, Chissov VI. Clinical oncopulmonology. Moscow: GEOTAR-Media, 2000 (in Russian).
3. The health consequences of smoking: a report of the Surgeon General. Available at: https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/consequences-smoking-factsheet/i.... Accessed: 26.08.2022.
4. The state of cancer care for the population of Russia in 2019. Ed. by AD Kaprin, VV Starinskii, AO Shakhzadova. Moscow: MNIOI im. PA Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2020 (in Russian).
5. Stahel R, Peters S, Garassino M. Thoracic tumours essentials for clinicians. ESMO Press, 2014.
6. WHO classification of tumours of the lung, pleura, thymus and heart, 2015.
7. The AJCC Cancer staging manual. 8th ed. Springer, 2017.
8. Grunnet M, Sorensen JB. Carcinoembrionic antigen (CEA) as a tumor marker in lung cancer. Lung Cancer. 2012;76:138-43.
9. Planchard D, Popat S, Kerr R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192-237.
10. NCCN Guidelines. Non-small cell lung cancer. Version 7.2019. Available at: https://www.nccn.org/guidelines/category_1. Accessed: 26.08.2022.
11. Travis DW, Brambilla E, Burke AP, et al. Classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2015.
12. Lung cancer. Ed. by FV Fossella, JB Putnam, R Komaki. NewYork: Springer, 2003.
13. Schrump DS, Carter D, Kelsey CR, et al. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg cancer. Principles and practice of oncology. Ed. by VT DeVita Jr, TS Lawrence, SA Rosenberg, et al. Philadelphia: Lippincott Williams and Wilkins, 2011.
14. Trakhtenberg AKh, Chissov VI, Frank GA. Neuroendocrine lung tumors. Moscow: Prakticheskaia meditsina, 2012 (in Russian).
15. Allakhverdiev AK, Davydov MM. Torakoskopicheskaia lobektomiia s mediastinal'noi limfodissektsiei standart v khirurgicheskom lechenii bol'nykh nemelkokletochnym rakom legkogo T1–2N0M0. Voprosy onkologii. 2015;61(3):413-7 (in Russian).
16. Higuchi M, Yaginuma H, Yonechi A, et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer. J Cardiothorac Surg. 2014;9:88-92.
17. Lindberg K, Nyman J, Riesenfeld Källskog V, et al. Long-term of a results of prospective trial phase II of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. Acta Oncol. 2015;54:1096-104.
18. Zhang T, Guo Q, Zhang Y, et al. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. J Can Res Ther. 2018;14:139-44.
19. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-97.
20. Arriagada R, Dunant A, Pignon JP. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35-42. DOI:10.1200/JCO.2009.23.2272
21. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267-77.
22. Aureperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol. 2010;28:2181-90.
23. Tsitsias T, Boulemden A, Ang K, et al. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. J Eur Cardiothorac Surg. 2014;45:882-7.
24. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172-8.
25. Usami N, Yokoi K, Hasegawa Y, et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol. 2010;15:583-7.
26. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516-24.
27. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369(9577):1929-37. DOI:10.1016/S0140-6736(07)60714-4
28. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043-51.
29. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-24.
30. Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10(10):CD002142. DOI:10.1002/14651858.CD002142.pub4
31. Arriagada R, Bergman B, Dunant A, et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-60.
32. Kreuter M, Vansteenkiste J, Fishcer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013;24:986-92.
33. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-60.
34. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.
35. Gridelli С, Chen T, Ko A, et al. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug Des Devel Ther. 2018;12:1445-51. DOI:10.2147/DDDT.S155750
36. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer. 2015;87:232-40.
37. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953-62.
38. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol. 2002;20:3454-60.
39. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-99.
40. Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-7. DOI:10.1016/j.jtho.2020.12.015
41. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(30):3488-515.
42. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25:1681-90.
43. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
44. Yang JC, Wu YI, Shuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR-mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX‑Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol. 2015;16:141-51.
45. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25.
46. Solomon BJ, Mok T, Kim DW, et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2013;371:2167-77.
47. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND 4): a randomized, open-label, phase 3 study. Lancet. 2017;389:917-29.
48. Camidge DR, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX global study of alectinib (ALC) versus crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol. 2018;36(Suppl.):9043.
49. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-16.
50. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017;28(8):2002-8.
51. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8:1556-62.
52. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer. 1998;34:1710-4.
53. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317-23.
54. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-50.
55. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol. 2008;26:3543-51.
56. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909-24. DOI:10.1016/j.jtho.2021.07.009
57. Barlesi F, Scherpereel A, Rittmeywr A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. J Clin Oncol. 2013;31:3004-11.
58. Takagi Y, Hosomi Y, Sunami K, et al. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin-Pemetrexed Therapy for Non-Small Cell Lung Cancer. Oncologist. 2014;19(11):1194-9. DOI:10.1634/theoncologist.2014-0221
59. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
60. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010;5:CD007309.
61. Azzolic G, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology clinical practice guideline update of chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825-31.
62. D’Addario G, Pintile M, Leighi NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature. J Clin Oncol. 2005;23:2926-36.
63. Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31:2849-53.
64. Perevodchikova NI, Gorbunova VA. Guidelines for chemotherapy of tumor diseases. Moscow: Prakticheskaia meditsina, 2015 (in Russian).
65. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy in elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72.
66. Corre R, Greillier L, Le Caer H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34:1476-83.
67. Henry HD, Costa I, Goldwasser F, et al. Randomised, double-blind study of denosumab versus zoledronic acid in the treatment skeletal metastases in patients with advanced cancer (excluded breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32.
68. Zatloukal P, Kanitz E, Magyar P, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer. 1998;22:243-50.
69. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin- gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516-24. DOI:10.1200/JCO.2011.39.9782
70. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-62.
71. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol. 2009;27:591-8.
72. Hanna NH, Sheperd FA, Fossella FV, et al. Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
73. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-21.
74. Cardenal F, López-Cabrerizon MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(1):12-8.
75. Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112-24.
76. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33. DOI:10.1056/NEJMoa1606774
77. Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36(Suppl. 18):LBA4.
78. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-92. DOI:10.1056/NEJMoa1801005
79. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-51.
80. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab in first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301.
81. Gandhi I, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-92.
82. Sheperd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum – based chemotherapy. J Clin Oncol. 2000;18:2095-103.
83. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
84. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
85. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-65.
86. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-50.
87. Herbst R, Garon E, Kim DW, et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thoracic Oncol. 2017;12:254-5.
88. Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29(11):2208-13.
89. Garon E, Reck M, Rodríguez-Abreu D, et al. P3.02c-030 Use of a 200‑Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: IT. J Thorac Oncol. 2017;12(1):S1290-91. DOI:10.1016/j.jthе.2016.11.1825
90. Morrissey KM, Marchand M, Patel H, et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019;84(6):1257-67. DOI:10.1007/s00280-019-03954-8
91. Garassino M, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981-8.
92. Novello S, Kaiser R, Mellengaard A, et al. Analysis of patient-reported outcomes from the LUME-Lung I trial: a randomized, double-blind, placebo-controlled. Phase III study of second line nintedanib in patients non-small-cell lung cancer. Eur J Cancer. 2015;51:317-26.
93. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. The European Lung Cancer Working Party. Lung Cancer. 2000;29:67-73.
94. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300-8.
95. Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119:2754-64.
96. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897-907.
97. Planchard D, Popat S, Kerr R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192-237.
98. Ahn MJ, Kim SW, Cho BC, et al. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. Oncologist. 2014;19(7):702-3.
99. Cho BC, Kim DW, Bearz A, et al. ASCEND-8 – a randomized phase I study ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK) rearranged metastatic non-small-cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357-67. DOI:10.1016/j.jtho.2017.07.005
100. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394-400.
101. Riely GJ, Yu HA. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res. 2015;21(10):2221-6. DOI:10.1158/1078-0432.CCR-14-3154
102. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
103. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
104. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. DOI:10.1056/NEJMoa0810699
105. Sequst LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-34.
106. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-25. DOI:10.1056/NEJMoa1713137
107. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
108. Oxnard GR, Thress KS, Alden RS. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3375-82. DOI:10.1200/JCO.2016.66.7162
109. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71.
110. Shaw AT, Yeap BY, Solomon BJ, et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. J Clin Oncol. 2011;29(Suppl. 15):7507.
111. Moro-Sibilot D, Faivre L, Zalcman G, et al. Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSE phase II trial. J Clin Oncol. 2015;33:abstr8065.
112. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-9.
113. Pan J. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. Clin Drug Investig. 2019;39:1003-7.
114. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-6.
115. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984-93.
116. Planchard D, Smit EF, Groen HJM, et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D+ trametinib (T) in the phase II BRF113928 study. J Clin Oncol. 2017;35(Suppl.):аbstr9075.
117. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28:29-34.
118. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacisumab with paclitaxel/carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2010;5:1416-23.
119. Yang B, Lee H, Um SW, et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer. 2019;129:28-34.
120. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.
121. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711-7.
122. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data of meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91:710-7.
123. Priestman TJ, Dunn J, Brada M, et al. Final results of the Royal College of Radiologists’ Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol. 1996;8:308-15.
124. Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg Clin North Am. 1996;7:435-46.
125. Naruke T. Lymph node metastasis of lung cancer and associated surgery. Asian Med J. 1990;33(12):668-77.
126. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database. J Thorac Cardiovasc Surg. 2010;139:366-78.
127. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial. J Thorac Cardiovasc Surg. 2010;139:976-81.
128. Ginsberg RJ, Rubinstein LV. Randomised trial of lobectomy versus limited resection for Т1N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615‑22.
129. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350-7.
130. Small cell lung cancer. Ed. by MB Bychkov. Moscow: Farmarus print Media, 2013 (in Russian).
131. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543-52.
132. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-71.
133. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810-6.
134. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-8.
135. Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9.
136. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.
137. Kelly K. Irinotecan in small-cell lung cancer: current data. Clin Lung Cancer. 2001;2(Suppl. 2):S4-8. DOI:10.3816/clc.2001.s.001
138. Chang AY, Rubins J, Asbury R, et al. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol. 2001;28(4 Suppl. 14):10-3.  DOI:10.1053/sonc.2001.27607
139. Smit E, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77(2):347-51.
140. Slotman B, Faivre-Finn C, Kramer G, et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664-72.
141. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42.
142. Sommer MS, Trier K, Vibe-Petersen J, et al. Perioperative rehabilitation in operation for lung cancer (PROLUCA) – rationale and design. BMC Cancer. 2014;14:404. DOI:10.1186/1471-2407-14-404
143. Sebio R, Yáñez-Brage MI, Giménez-Moolhuyzen E, et al. Impact of a pre-operative pulmonary rehabilitation program on functional performance in patients undergoing video-assisted thoracic surgery for lung cancer. Arch Bronconeumol. 2016;52(5):231-2.
144. Sebio GR, Yáñez Brage MI, Giménez Moolhuyzen E, et al. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(3):486-97.
145. Barassi G, Bellomo RG, Di Iulio A, et al. Preoperative rehabilitation in lung cancer patients: yoga approach. Adv Exp Med Biol. 2018;1096:19-29.
146. Rogers LJ, Bleetman D, Messenger DE, et al. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. J Thorac Cardiovasc Surg. 2018;155(4):1843-52.
147. Li S, Zhou K, Che G, et al. Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res. 2017;9:657-70. DOI:10.2147/CMAR.S150500
148. Deng GE, Rausch SM, Jones LW, et al. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(Suppl. 5):e420S-36S.
149. Imperatori A, Grande A, Castiglioni M, et al. Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Interact Cardiovasc Thorac Surg. 2016;23:223-30.
150. Park H, Park J, Woo SY, et al. Effect of high-frequency chest wall oscillation on pulmonary function after pulmonary lobectomy for non-small cell lung cancer. Crit Care Med. 2012;40(9):2583-9.
151. Dhillon HM, van der Ploeg HP, Bell ML, et al. The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer. 2012;12:572.
152. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42:1409-26.
153. Janssen SM, Abbink JJ, Lindeboom R, Vliet Vlieland TP. Outcomes of pulmonary rehabilitation after treatment for non-small cell lung cancer stages I to IIIa: an observational study. J Cardiopulm Rehabil Prev. 2017;37(1):65-71.
154. Sun V, Raz DJ, Ruel N, et al. A multimedia self-management intervention to prepare cancer patients and family caregivers for lung surgery and postoperative recovery. Clin Lung Cancer. 2017;18(3):e151-9.
155. Batty GD, Russ TC, Stamatakis E, Kivimäki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ. 2017;356:j108.
156. Luszczynska A, Pawłowska I, Cieslak R, et al. Social support and quality of life among lung cancer patients: a systematic review. Psychooncology. 2013;22(10):2160-8.
157. Li M, Kennedy E, Byrne N, et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology. 2017;26:573-87.
158. Rivas-Perez H, Nana-Sinkam P. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med. 2015;109(4):437-42.
159. Andrea L, Kollasch J, Vandenberg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013;45:811-21.
160. Hilliard RE. Music therapy in hospice and palliative care: a review of the empirical data. Evid Based Complement Alternat Med. 2005;2(2):173-8.
161. Chen HY, Li SG, Cho WCS, Zhang ZJ. The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis. BMC Complement Altern Med. 2013;13:362.
162. Streckmann F, Zopf EM, Lehmann HC, et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014;44:1289-304.
163. Muzi JL, Look RM, Turner C, et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2012;30(Suppl. 15):9019.
164. Rick O, von Hehn U, Mikus E, et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics. 2016;38(2):85-94.
165. Kilinç M, Livanelioglu A, Yildirim SA, Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014;46(5):454-60.
166. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107418.
167. Ross M, Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs. 2017;21(2):226-33.
168. Hetkamp M, Bender J, Rheindorf N, et al. A Systematic Review of the Effect of Neurofeedback in Cancer Patients. Integr Cancer Ther. 2019;18:1534735419832361. DOI:10.1177/1534735419832361
169. Bade BC, Thomas DD, Scott JB, Silvestri GA. Increasing physical activity and exercise in lung cancer: reviewing safety, benefits, and application. J Thorac Oncol. 2015;10(6):861-71.
170. Bensadoun RJ, Nair RG. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg. 2015;33(10):487-91.
171. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372-90.
172. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. Ed. by C MacLeod. New York: Columbia University Press, 1949.
173. Hendriks LEL, Hermans BCM, Marieke van den Beuken-van Everdingen HJ, et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review. J Thorac Oncol. 2016;11(2):155-73.
174. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-35.
175. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018;13(9):1248-68.
176. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631-41.
177. Oxnard GR, Thress KS, Alden RS. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3375-82.  DOI:10.1200/JCO.2016.66.7162
178. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016;2(8):1014-22.
179. Kate S, Chougule A, Joshi A, et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl). 2019;10:1-10.
180. Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488-95.
181. Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302-16.
182. Passaro A, Pochesci A, Spitaleri G, et al. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7. J Thorac Dis. 2016;8(3):E217-20.
183. Takeda Y, Naka G, Yamaguchi Y, et al. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. BMC Cancer. 2020;20(1):951. DOI:10.1186/s12885-020-07424-w
184. NCCN Guidelines. Non-small cell lung cancer. Version 6.2020. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed: 26.08.2022.
185. Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44-56.
186. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-43.
187. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147.
188. Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019;3. DOI:10.1200/PO.19.00171
189. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):909-20.
190. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
191. Kowanetz M, Zou W, Shames DS, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Ann Oncol. 2016;27(Suppl. 6). DOI:10.1093/annonc/mdw363.25
192. Ramalingam S, Hellmann MD, Awad MM, et al. Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab + ipilimumab in first-line non-small cell lung cancer: identification of TMB cutoff from Checkmate 568. In: AACR Annual Meeting. 2018:abstr11317.
193. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.
194. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. In: 2018 Genitourinary Cancer Symposium. Lancet. 2018;391(10122):748-57. DOI:10.1016/S0140-6736(17)33297-X
195. Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71:177.
196. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv1-21.
197. Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162-74.
198. De Wever W. Role of integrated PET/CT in the staging of non-small cell lung cancer. JBR-BTR. 2009;92:124.
199. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl. 5):e211S-50S. DOI:10.1378/chest.12-2355
200. National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243-53. DOI:10.1148/radiol.10091808
201. National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980.
202. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-13.
203. Sadate A, Occean BV, Beregi JP, et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer. 2020;134:107.
204. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation-positive NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(Suppl. 18):LBA5. DOI:10.1200/JCO.2020.38.18_suppl.LBA5
205. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-704.
206. Ahn JS, Ahn YC, Kim JH, et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-6.  DOI:10.1200/JCO.2014.60.0130
207. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942-6.
208. Camidge RD, Ou SHI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol. 2014;32(Suppl. 5):abstr8001.
209. Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018;36(24):2532-7.
210. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-104.
211. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415-426.
212. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5.
213. Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28(2):292-7.
214. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47-51.
215. Spigel D, De Marinis F, Giaccone G, et al. IMpower110: Interim OS Analysis of a Phase III Study of Atezolizumab (atezo) vs Platinum-Based Chemotherapy (chemo) as 1L Treatment (tx) in PD-L1-selected NSCLC. ESMO 2019 (abstr:LBA78). Ann Oncol. 2019;30(Suppl. 5):v851-934.  DOI:10.1093/annonc/mdz394
216. Herbst RS, de Marinis F, Giaccone G, et al. LBA1 Clinical efficacy of Atezolizumab (Atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunochistochemistry (IHC) assys and by blood tumor mutational burden (bTMB): results from the IMpower110 study. Ann Oncol. 2019;30(Suppl. 11):xi62-8.
217. Chou CH, Hsu LF. Model-based simulation to support the extended dosing regimens of atezolizumab. Eur J Clin Pharmacol. 2021;77(1):87-93.  DOI:10.1007/s00228-020-02980-3
218. Hellman MD, Paz-Ares L, Caro RB, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020-31.
219. Reck M, Ciuleanu TD, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38(15):9501.
220. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68-75. DOI:10.1016/j.ejca.2020.02.016
221. Grohé C, Gleiber W, Haas S, et al. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncol. 2019;15(23):2699‑706. DOI:10.2217/fon-2019-0262
222. Nakagawa K, Garon E, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-69.
223. Garon E, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73.
224. Stinchcombe TE, Jänne PA, Wang X, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1448-55. DOI:10.1001/jamaoncol.2019.1847
225. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-64. DOI:10.1016/j.annonc.2020.04.478
226. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. J Clin Oncol. 2020;38(Suppl. 15):9002. DOI:10.1200/JCO.2020.38.15_suppl.9002
227. Chen Y, Paz-Ares L, Dvorkin M, et al. First-line durvalumab plus platinum-etoposide in ES-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. J Clin Oncol. 2020;38(Suppl. 15):9068.  DOI:10.1200/JCO.2020.38.15_suppl.9068.
228. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 3.2020. 2020. Available at: www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed: 06.09.2022.
229. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-67. DOI:10.1016/S1470-2045(18)30649-1
230. Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32(5):620-30. DOI:10.1016/j.annonc.2021.02.012
231. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected Stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15 Suppl.):8500. DOI:10.1200/JCO.2021.39.15_SUPPL.8500
232. Brueckl WM, Reck M, Rittmeyer A, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clin Med Insights Oncol. 2020;14:1179554920951358. DOI:10.1177/1179554920951358
233. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer:  Version 3.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed: 06.09.2022.
234. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38(31):3592-603. DOI:10.1200/JCO.20.00505
235. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017;35(22):2490-8. DOI:10.1200/JCO.2016.71.5904
236. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491‑505. DOI:10.1016/j.annonc.2020.07.014
237. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann Oncol. 2018;29(9):1895‑902. DOI:10.1093/annonc/mdy263
238. Freiwald M, Schmid U, Fleury A, et al. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol. 2014;73(4):759-70. DOI:10.1007/s00280-014-2403-2
239. Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016;27(11):2103-10. DOI:10.1093/annonc/mdw322
240. Morrissey KM, Marchand M, Patel H, et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019;84(6):1257-67. DOI:10.1007/s00280-019-03954-8
241. Baverel PG, Dubois VFS, Jin CY, et al. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. Clin Pharmacol Ther. 2018;103(4):631-42. DOI:10.1002/cpt.982
242. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-95. DOI:10.1016/j.suponc.2011.05.002
243. Chen C, Li R, Yang T, et al. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Clin Ther. 2020;42(8):1494-507.e1. DOI:10.1016/j.clinthera.2020.05.019
244. Krishan S, Panditaratne N, Verma R, Robertson R. Incremental value of CT venography combined with pulmonary CT angiography for the detection of thromboembolic disease: systematic review and meta-analysis. AJR Am J Roentgenol. 2011;196(5):1065-72. DOI:10.2214/AJR.10.4745
245. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-56. DOI:10.1182/bloodadvances.2018024828
246. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74. DOI:10.1182/bloodadvances.2020003442
247. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. Version 1. 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed: 06.09.2022.
248. Kosaka Y, Rai Y, Masuda N, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer. 2015;23(4):1137-43. DOI:10.1007/s00520-014-2597-1
249. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176-89. DOI:10.1093/jac/dki448
250. Vincenzi B, Russo A, Terenzio A, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018;130:70-77. DOI:10.1016/j.critrevonc.2018.06.019
251. Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol. 2021;27(32):5376-91. DOI:10.3748/wjg.v27.i32.5376
252. Mao Z, Shen K, Zhu L, et al. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Oncol Res Treat. 2019;42(7-8):405-413. DOI:10.1159/000500204
253. Albakri A. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res. 2018;1(4). DOI:10.15761/TR.1000124
254. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73-84. DOI:10.1016/j.jchf.2021.09.004
255. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900-9. DOI:10.1016/j.ejca.2013.04.030
256. Li J, Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol. 2018;82(4):571-83. DOI:10.1007/s00280-018-3644-2
257. Martin EJ, Bruggeman AR, Nalawade VV, et al. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. J Natl Compr Canc Netw. 2020;18(5):569-74. DOI:10.6004/jnccn.2019.7524
258. de van der Schueren MAE, Laviano A, Blanchard H, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018;29(5):1141-53. DOI:10.1093/annonc/mdy114
259. Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open. 2018;3(2):e000301. DOI:10.1136/esmoopen-2017-000301
260. NCCN guidelines. Management of Immunotherapy-Related Toxicities.  Version 4. 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed: 06.09.2022. 
261. Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6(1):103. DOI:10.1186/s40425-018-0412-0
262. Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv126-42. DOI:10.1093/annonc/mdy145
263. Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl. 5):v261-5. DOI:10.1093/annonc/mdq197
264. Ohashi Y, Uemura Y, Fujisaka Y, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci. 2013;104(4):481-5. DOI:10.1111/cas.12105
265. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52(1):18-29.  DOI:10.3109/0284186X.2012.702921
266. Fallon M, Giusti R, Aielli F, et al; ESMO Guidelines Committee. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166-91. DOI:10.1093/annonc/mdy152
267. Capozzi VA, Monfardini L, Sozzi G, et al. Peripherally Inserted Central Venous Catheters (PICC) versus totally implantable venous access device (PORT) for chemotherapy administration: a meta-analysis on gynecological cancer patients. Acta Biomed. 2021;92(5):e2021257. DOI:10.23750/abm.v92i5.11844
268. Fallon M, Giusti R, Aielli F, et al. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines Ann Oncol. 2018;29(Suppl. 4):iv166-91. DOI:10.1093/annonc/mdy152
269. Giuliani M, Mathew AS, Bahig H, et al. SUNSET: Stereotactic Radiation for Ultracentral Non- Small-Cell Lung Cancer-A Safety and Efficacy Trial. Clin Lung Cancer. 2018;19(4):e529-32. DOI:10.1016/j.cllc.2018.04.001
270. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833-9. DOI:10.1200/JCO.2006.07.5937
271. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68-75. DOI:10.1016/j.ejca.2020.02.016
272. Comis RL, Friedland DM, Good BC. The role of oral etoposide in non-small cell lung cancer. Drugs. 1999;58(Suppl. 3):21-30. DOI:10.2165/00003495-199958003-00004
273. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810-6.  DOI:10.1093/annonc/mdq036
274. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for Еuropean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. DOI:10.1016/S1470-2045(11)70393-X

К.К. Лактионов1, Е.В. Артамонова1, Т.Н. Борисова1, В.В. Бредер1, Ю.М. Бычков2, Л.Ю. Владимирова1, Н.М. Волков3, С.М. Ергнян4, А.С. Жабина3, П.В. Кононец1, А.Е. Кузьминов1, Е.В. Левченко4, О.А. Малихова1, Д.Т. Маринов1,  С.В. Миллер5, Ф.В. Моисеенко3, В.В. Мочальникова1, С.Н. Новиков4, О.В. Пикин6, Е.В. Реутова1, Е.О. Родионов5, Д.Д. Сакаева7, К.А. Саранцева1, А.И. Семенова4, А.В. Смолин8, В.М. Сотников2, С.А. Тузиков5, И.Н. Туркин9,  И.Е. Тюрин10, В.Д. Чхиквадзе2, К.И. Колбанов6, М.В. Черных1,11,12, А.В. Черниченко6, А.А. Феденко6,  Е.В. Филоненко6, А.А. Невольских13, С.А. Иванов13, Ж.В. Хайлова13, Т.Г. Геворкян1, А.В. Бутенко1,  И.Р. Гильмутдинова14, И.В. Гриднева15, М.А. Еремушкин14, М.А. Зернова4, Б.С. Каспаров4, Д.В. Ковлен16,  К.О. Кондратьева4, Т.В. Кончугова14, С.Б. Короткова15, А.А. Крутов4, О.А. Обухова1, Г.Н. Пономаренко16,17,  Т.Ю. Семиглазова4,18, А.М. Степанова19, М.М. Хуламханова1

1 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
2 ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России, Москва, Россия; 3 ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)», Санкт-Петербург, Россия;
4 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России, Санкт-Петербург, Россия;
5 ФГБНУ «Томский национальный исследовательский медицинский центр» РАН, Томск, Россия; 6 Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия;
7 ГБУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики Башкортостан, Уфа, Россия;
8 ФГБУ «Главный военный клинический госпиталь им. акад. Н.Н. Бурденко» Минобороны России, Москва, Россия;
9 ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России, Ростов-на-Дону, Россия;
10 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»  Минздрава России, Москва, Россия;
11 ГК «МедИнвестГрупп», Москва, Россия;
12 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия; 
13 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
14 ФГБУ «Национальный медицинский исследовательский центр реабилитации и курортологии» Минздрава России, Москва, Россия;
15 ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России, Воронеж, Россия;
16 Филиал ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Москва, Россия;
17 ФГБУ «Федеральный научный центр реабилитации инвалидов им. Г.А. Альбрехта» Минтруда России,  Санкт-Петербург, Россия;
18 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия;
19 Центр диагностики и реабилитации «Восстановление», Москва, Россия

________________________________________________

Konstantin K. Laktionov1, Elena V. Artamonova1, Tatiana N. Borisova1, Valeriy V. Breder1, Iurii M. Bychkov2,  Liubov Iu. Vladimirova1, Nikita M. Volkov3, Stepan M. Ergnian4, Albina S. Zhabina3, Pavel V. Kononets1,  Alexander E. Kuzminov1, Evgeny V. Levchenko4, Olga A. Malikhova1, Dimitr T. Marinov1, Sergey V. Miller5,  Fedor V. Moiseenko3, Valeriia V. Mochal'nikova1, Sergei N. Novikov4, Oleg V. Pikin6, Elena V. Reutova1,  Evgenii O. Rodionov5, Dina D. Sakaeva7, Ksenia A. Sarantseva1, Anna I. Semenova4, Aleksei V. Smolin8,  Vladimir M. Sotnikov2, Sergei A. Tuzikov5, Igor N. Turkin9, Igor E. Tyurin10, Vladimir D. Chkhikvadze2,  Konstantin I. Kolbanov6, Marina V. Chernykh1,11,12, Andrei V. Chernichenko6, Aleksandr A. Fedenko6,  Elena V. Filonenko6, Aleksei A. Nevol'skikh13, Sergei A. Ivanov13, Zhanna V. Khailova13, Tigran G. Gevorkian1,  Aleksei V. Butenko1, Ilmira R. Gil'mutdinova14, Irina V. Gridneva15, Mihail A. Eremushkin14, Margarita A. Zernova4, Boris S. Kasparov4, Denis V. Kovlen16, Kristina O. Kondrat'eva4, Tatiana V. Konchugova14, Svetlana B. Korotkova15, Anton A. Krutov4, Olga A. Obukhova1, Gennadii N. Ponomarenko16,17, Tatiana Iu. Semiglazova4,18,  Aleksandra M. Stepanova19, Marina M. Khulamkhanova1

1 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
2 Russian Scientific Center of Roentgenoradiology, Moscow, Russia;
3 Saint Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncologic),  Saint Petersburg, Russia;
4 Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia;
5 Tomsk National Research Medical Center, Tomsk, Russia;
6 Herzen Moscow Scientifuc Research Institute of Oncology – branch of the National Medical Research Center for Radiology, Moscow, Russia;
7 Republican Clinical Oncology Center, Ufa, Russia;
8 Burdenko Main Military Clinical Hospital, Moscow, Russia;
9 Rostov Research Institute of Oncology, Rostov-on-Don, Russia;
10 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
11 GC “MedInvestGroup”, Moscow, Russia;
12 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 
13 Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology, Obninsk, Russia;
14 National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia;
15 Burdenko Voronezh State Medical University, Voronezh, Russia;
16 Branch of Kirov Military Medical Academy, Moscow, Russia;
17 Albrecht Federal Scientific Center for Rehabilitation of Disabled People, Saint Petersburg, Russia; 18 Mechnikov North-Western State Medical University, Saint Petersburg, Russia;
19 Diagnostic and Rehabilitation Center “Recovery”, Moscow, Russia